Dianax

We are seeing a tectonic shift in healthcare infrastructure as we know it, powered by the smartphone revolution, and dianax is at the cutting-edge of mobile diagnostic transformation. The ongoing development of dianax lab-on-a-chip has been made possible thanks to investment from multiple sources. We are indebted to those in the European Commission who recognized early on the extraordinary potential of our technology in changing the face of diagnostic testing and awarded a significant grant through their Horizon 2020 Program. We are always happy to hear from interested parties. We have partnered with experts in rapid diagnostics – BioSpeedia (a spin-off of Institut Pasteur) – to bring to market a reliable test for rapid detection and differentiation of antibodies to novel coronavirus SARS-CoV-2. The COVID19SEROSpeed-IgM-IgG Rapid Test is now distributed by dianax in Italy, Belgium, Luxembourg, the Netherlands, Greece, Spain and Portugal. By bringing laboratory-grade disease screening, diagnosis and monitoring to the patient, dianax is taking diagnostics straight to the POINT OF NEED. While HbA1c-glycated hemoglobin blood testing for diabetes is our primary focus, the dianax lab-on-a-chip can test any protein extracted from bodily fluids (blood, urine, saliva), and so has the potential to transform diagnostic testing across a number of therapy areas.